PMID- 23527713
OWN - NLM
STAT- MEDLINE
DCOM- 20130910
LR  - 20170214
IS  - 0394-6320 (Print)
IS  - 0394-6320 (Linking)
VI  - 26
IP  - 1
DP  - 2013 Jan-Mar
TI  - Antidepressant drug, desipramine, alleviates allergic rhinitis by regulating Treg 
      and Th17 cells.
PG  - 107-15
AB  - Allergic rhinitis (AR) is characterized by IgE-mediated immediate 
      hypersensitivity and usually progresses to chronic nasal inflammation, with 
      depression as one of its comorbidities. The importance of treating the depression 
      in AR patients has been increasingly recognized. Desipramine is a representative 
      of tricyclic-antidepressant agents. In the present study we investigate whether 
      desipramine has therapeutic effects on AR inflammation. BALB/C mice were 
      sensitized by intraperitoneal injection of ovalbumin (OVA), followed by repeated 
      challenge with OVA intranasally. Desipramine was administered orally to treat the 
      mice. The nasal symptoms (sneezing, nasal scratching etc.) of AR were evaluated 
      to determine the severity of AR. Cytokines in the nasal lavage fluid (NALF), 
      including interferon-gamma (IFN-gamma), interleukin 4 (IL-4) and serum 
      OVA-specific immunoglobulin E (IgE) antibody were measured by ELISA. The 
      regulatory T cells (Treg) and T helper cells 17 (Th17) were quantified by flow 
      cytometric analysis. As a result, the repeated oral administration of desipramine 
      attenuated the nasal symptoms (sneezing and nasal rubbing) in AR mice. 
      Desipramine also suppressed the serum OVA-specific IgE and IL-4 levels, but had 
      no effect on IFN-gamma level. Moreover, desipramine treatment up regulated 
      CD4+CD25+Foxp3+ Treg cells, which were found down-regulated in established AR 
      mice. Meanwhile, desipramine administration attenuated CD4+IL-17+ Th17 cells, 
      which were significantly increased in AR mice. These results suggest that the 
      antidepressant drug, desipramine, also has anti-allergic action, which was 
      possibly achieved by reducing allergen-specific IgE and Th2 cytokine production 
      and maintaining a balance between Treg and Th17 cells. Thus, this study provide 
      the first evidence that desipramine may be utilized to treat allergic diseases, 
      especially for those allergic patients with depression or depression patients 
      with allergy.
FAU - Zhang, Y
AU  - Zhang Y
AD  - Department of Pharmacology, Huazhong University of Science and Technology, China.
FAU - Zhen, H
AU  - Zhen H
FAU - Yao, W
AU  - Yao W
FAU - Bian, F
AU  - Bian F
FAU - Mao, X
AU  - Mao X
FAU - Yang, X
AU  - Yang X
FAU - Jin, S
AU  - Jin S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Immunopathol Pharmacol
JT  - International journal of immunopathology and pharmacology
JID - 8911335
RN  - 0 (Allergens)
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antidepressive Agents)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9006-59-1 (Ovalbumin)
RN  - TG537D343B (Desipramine)
SB  - IM
MH  - Allergens/immunology
MH  - Animals
MH  - Anti-Allergic Agents/pharmacology/*therapeutic use
MH  - Antidepressive Agents/pharmacology/*therapeutic use
MH  - Desipramine/pharmacology/*therapeutic use
MH  - Immunoglobulin E/blood
MH  - Interferon-gamma/immunology
MH  - Interleukin-4/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nasal Lavage Fluid/immunology
MH  - Ovalbumin/immunology
MH  - Rhinitis, Allergic
MH  - Rhinitis, Allergic, Perennial/*drug therapy/immunology
MH  - Spleen/cytology/immunology
MH  - T-Lymphocytes, Regulatory/drug effects/immunology
MH  - Th17 Cells/drug effects/immunology
EDAT- 2013/03/27 06:00
MHDA- 2013/09/11 06:00
CRDT- 2013/03/27 06:00
PHST- 2013/03/27 06:00 [entrez]
PHST- 2013/03/27 06:00 [pubmed]
PHST- 2013/09/11 06:00 [medline]
AID - 10 [pii]
AID - 10.1177/039463201302600110 [doi]
PST - ppublish
SO  - Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):107-15. doi: 
      10.1177/039463201302600110.